Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
Eterna Therapeutics (ERNA) has announced a research initiative to study ERNA-101, its lead induced mesenchymal stem cell therapy candidate, in ovarian and breast cancer models through a collaboration with MD Anderson Cancer Center. The research will examine ERNA-101's ability to induce and modulate antitumor immunity. ERNA-101 is an allogenic cell therapy derived from iPSCs that secretes IL-7 and IL-15. Based on the results, future studies may evaluate combinations with CAR T or CAR NK cell therapies in solid tumors. The project aims to generate data supporting ERNA-101's IND submission.
Eterna Therapeutics (ERNA) ha annunciato un'iniziativa di ricerca per studiare ERNA-101, il suo principale candidato per la terapia con cellule staminali mesenchimali indotte, in modelli di cancro ovarico e mammario attraverso una collaborazione con il MD Anderson Cancer Center. La ricerca esaminerà la capacità di ERNA-101 di indurre e modulare l'immunità antitumorale. ERNA-101 è una terapia cellulare allogenica derivata da iPSC che secerne IL-7 e IL-15. Sulla base dei risultati, studi futuri potrebbero valutare combinazioni con terapie CAR T o CAR NK in tumori solidi. Il progetto mira a generare dati a supporto della domanda IND per ERNA-101.
Eterna Therapeutics (ERNA) ha anunciado una iniciativa de investigación para estudiar ERNA-101, su candidato principal para la terapia con células madre mesenquimatosas inducidas, en modelos de cáncer de ovario y de mama a través de una colaboración con el MD Anderson Cancer Center. La investigación examinará la capacidad de ERNA-101 para inducir y modular la inmunidad antitumoral. ERNA-101 es una terapia celular alogénica derivada de iPSCs que secreta IL-7 e IL-15. En función de los resultados, los futuros estudios podrían evaluar combinaciones con terapias de células CAR T o CAR NK en tumores sólidos. El proyecto tiene como objetivo generar datos que apoyen la presentación IND de ERNA-101.
에테르나 테라퓨틱스 (ERNA)는 MD 앤더슨 암 센터와의 협력을 통해 난소암 및 유방암 모델에서 자사의 주요 유도 중간엽 줄기세포 치료 후보인 ERNA-101을 연구하는 이니셔티브를 발표했습니다. 이 연구는 ERNA-101이 항종양 면역을 유도하고 조절하는 능력을 조사할 것입니다. ERNA-101은 iPSC에서 유래된 알로겐 세포 치료제로 IL-7과 IL-15를 분비합니다. 결과에 따라 향후 연구에서는 고형 종양에서 CAR T 또는 CAR NK 세포 치료와의 조합을 평가할 수 있습니다. 이 프로젝트는 ERNA-101의 IND 제출을 지원하는 데이터를 생성하는 것을 목표로 합니다.
Eterna Therapeutics (ERNA) a annoncé une initiative de recherche pour étudier ERNA-101, son principal candidat en thérapie cellulaire mésenchymateuse induite, dans des modèles de cancer de l'ovaire et du sein, en collaboration avec le MD Anderson Cancer Center. La recherche examinera la capacité de ERNA-101 à induire et moduler l'immunité antitumorale. ERNA-101 est une thérapie cellulaire allogénique dérivée de iPSC qui sécrète IL-7 et IL-15. En fonction des résultats, des études futures pourraient évaluer des combinaisons avec des thérapies CAR T ou CAR NK dans des tumeurs solides. Le projet vise à générer des données soutenant la soumission de l'IND pour ERNA-101.
Eterna Therapeutics (ERNA) hat eine Forschungsinitiative angekündigt, um ERNA-101, den führenden Kandidaten für die Therapie mit induzierten mesenchymalen Stammzellen, in Modellen von Eierstock- und Brustkrebs in Zusammenarbeit mit dem MD Anderson Cancer Center zu untersuchen. Die Forschung wird die Fähigkeit von ERNA-101 untersuchen, die antitumorale Immunität zu induzieren und zu modulieren. ERNA-101 ist eine allogene Zelltherapie, die aus iPSCs gewonnen wird und IL-7 und IL-15 sezerniert. Basierend auf den Ergebnissen könnten zukünftige Studien Kombinationen mit CAR T- oder CAR NK-Zelltherapien bei soliden Tumoren bewerten. Das Projekt zielt darauf ab, Daten zur Unterstützung der IND-Einreichung von ERNA-101 zu generieren.
- Research partnership established with prestigious MD Anderson Cancer Center
- Potential pathway for IND submission advancement
- Possible expansion into combination therapies with CAR T/NK cells
- Early-stage research with no guaranteed clinical success
- No immediate revenue potential from this research initiative
Insights
The launch of research to evaluate ERNA-101's potential in ovarian and breast cancer represents a significant preclinical development milestone. The study's focus on immunomodulatory effects and antitumor immunity could provide important data for advancing this novel cell therapy approach. The collaboration with MD Anderson Cancer Center, particularly with Dr. Andreeff who co-developed the cells, adds substantial credibility to the research program.
The technology combines several innovative elements:
- iPSC-derived mesenchymal stem cells
- IL-7 and IL-15 secretion capabilities
- Potential synergy with CAR T or CAR NK cell therapies
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA) today announced it will investigate the ability of its lead iMSC-based cell therapy (ERNA-101) to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research agreement with The University of Texas MD Anderson Cancer Center. ERNA-101 is Eterna’s proprietary allogenic IL-7 and IL-15-secreting induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (iMSC) product candidate.
Researchers will investigate immunomodulatory effects of ERNA-101 in vitro and antitumor immunity of ERNA-101 in ovarian cancer and breast cancer models in vivo. Based on results from these studies, future research may evaluate ERNA-101 combined with CAR T or CAR NK - cell therapies in solid tumors. The studies will be led by Michael Andreeff, MD, PhD, Professor of Leukemia at MD Anderson, who also jointly developed the ERNA-101 cells with Eterna.
“This research project is pivotal in accelerating ERNA-101’s pathway to IND submission,” said Sanjeev Luther, CEO and President of Eterna. “Through this agreement, we aim to generate the data needed to demonstrate ERNA-101’s therapeutic potential in solid tumors.”
About Eterna Therapeutics Inc.
Eterna Therapeutics is a publicly traded, preclinical-stage company focused on using cutting-edge tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors, with an initial emphasis on platinum-resistant ovarian cancer and triple-negative breast cancer (TNBC). The company is currently focused on advancing its lead product ERNA-101, an induced allogenic mesenchymal stem cell (iMSC) product, designed to selectively deliver the pro-inflammatory cytokines IL-7 and IL-15 to the tumor microenvironment (TME) in order to drive significant anti-tumor immunity. ERNA-101 is built on the company's in-licensed core technology, which utilizes a best-in-class approach to engineer allogenic iPSCs to express genes of interest and to efficiently differentiate these cells into iMSCs. For more information, please visit https://www.eternatx.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Eterna's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Eterna's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Investor Relations Contact:
investors@eternatx.com
FAQ
What is ERNA-101 and how does it work in cancer treatment?
Which cancer types is Eterna Therapeutics (ERNA) targeting with ERNA-101?
What is the purpose of Eterna Therapeutics' (ERNA) research agreement with MD Anderson?
Will ERNA-101 be combined with other cancer therapies?
